TOM DULEY has extensive experience representing life sciences companies in a wide range of technology and intellectual property transactions, including strategic collaborations, joint ventures, licenses, asset purchase and sale transactions and other commercial transactions. Tom brings problem-solving creativity and operational experience to clients ranging from startups to large public corporations. His experience also includes numerous cross-border transactions, including working with clients to develop and commercialize products in China. From 2006 to 2008, Tom was Senior Corporate Counsel at PDL Biopharma (NASDAQ: PDLI).
“Tom is really terrific. He looks at size and scope and what the company really needs for the transaction. He knows his craft and how to manage a project.”
Chambers USA 2023
Tom was recognized in the 2022–2023 editions of Chambers USA in Life Sciences: Corporate/Commercial in California with clients noting, “Thomas is an excellent lawyer and an excellent advocate for his clients” (2022). He accepted the “Financial & Corporate Impact Deal of the Year” at the 2019 Legal Media Group (LMG) Life Sciences Awards for Sidley’s representation of Nurix Therapeutics in its collaboration with Gilead Sciences valued at US$2.48 billion. In addition, he was named “Finance & Transactional Attorney of the Year: Licensing & Collaboration” by LMG Life Sciences in 2018, and was named a “Life Sciences Star” for the Licensing & Collaboration category (2019–2023). Tom also received the “Trusted Advisor” award from The Recorder in 2017.